MedTrace Logo

Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

NCT02274259 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-12-04

No results posted yet for this study

Summary

Comparing ranibizumab and aflibercept in a treat and extend algorithm evaluating the number of needed injections over a 18 month period in patients with newly diagnosed CRVO.

Conditions

  • Central Retinal Vein Occlusion

Interventions

DRUG

Aflibercept

Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema

DRUG

Ranibizumab

Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema

Sponsors & Collaborators

  • Anders Kvanta

    lead OTHER

Principal Investigators

  • Sofie Westman · Study coordinator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-06-30
Completion
2016-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02274259 on ClinicalTrials.gov